AU8216398A - Treatment of diabetes with rosiglitazone and insulin - Google Patents

Treatment of diabetes with rosiglitazone and insulin Download PDF

Info

Publication number
AU8216398A
AU8216398A AU82163/98A AU8216398A AU8216398A AU 8216398 A AU8216398 A AU 8216398A AU 82163/98 A AU82163/98 A AU 82163/98A AU 8216398 A AU8216398 A AU 8216398A AU 8216398 A AU8216398 A AU 8216398A
Authority
AU
Australia
Prior art keywords
compound
administration
insulin
pharmaceutically acceptable
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU82163/98A
Other languages
English (en)
Inventor
Stephen Alistair Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU8216398A publication Critical patent/AU8216398A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU82163/98A 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin Abandoned AU8216398A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9712866 1997-06-18
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
PCT/EP1998/003692 WO1998057636A1 (fr) 1997-06-18 1998-06-15 Nouvelle methode de traitement

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU15521/02A Division AU1552102A (en) 1997-06-18 2002-02-08 Treatment of diabetes with rosiglitazone and insulin

Publications (1)

Publication Number Publication Date
AU8216398A true AU8216398A (en) 1999-01-04

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
AU82163/98A Abandoned AU8216398A (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin

Country Status (30)

Country Link
EP (1) EP0999837A1 (fr)
JP (1) JP2002504138A (fr)
KR (1) KR20010013843A (fr)
CN (1) CN1133431C (fr)
AP (1) AP1287A (fr)
AR (2) AR015894A1 (fr)
AU (1) AU8216398A (fr)
BG (1) BG104059A (fr)
BR (1) BR9810444A (fr)
CA (1) CA2294141A1 (fr)
CO (1) CO4940454A1 (fr)
DZ (1) DZ2521A1 (fr)
EA (1) EA004800B1 (fr)
GB (1) GB9712866D0 (fr)
HU (1) HUP0003260A3 (fr)
ID (1) ID23951A (fr)
IL (1) IL133143A0 (fr)
IN (1) IN189723B (fr)
MA (1) MA26511A1 (fr)
NO (1) NO996265L (fr)
OA (1) OA11517A (fr)
PE (1) PE104499A1 (fr)
PL (1) PL343123A1 (fr)
SK (1) SK179399A3 (fr)
TR (1) TR199903095T2 (fr)
TW (1) TW587937B (fr)
UA (1) UA70299C2 (fr)
UY (1) UY25050A1 (fr)
WO (1) WO1998057636A1 (fr)
ZA (1) ZA985237B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
DZ3155A1 (fr) 1999-04-23 2000-11-02 Smithkline Beecham Plc Nouvelle composition pharmaceutique.
DK1133312T3 (da) * 1999-06-21 2008-01-02 Lilly Co Eli Synergistisk anvendelse af thiazolidindioner med glucagonlignende peptid-1 og agonister deraf til behandling af ikke-insulinafhængig diabetes
AU5760900A (en) 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
BR0316091A (pt) * 2002-11-08 2005-09-27 Hoffmann La Roche Compostos, processo para a manufatura dos mesmos, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(a) e/ou ppar(y) e/ou utilização dos mesmos
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (zh) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 含有罗格列酮和盐酸西替利嗪的固体口服制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228260B1 (en) * 1993-09-15 2013-02-28 Daiichi Sankyo Company Pharmaceutical compositions to treat impaired glucose tolerance
CN1192683A (zh) * 1995-08-10 1998-09-09 沃尼尔·朗伯公司 减少非胰岛素依赖型糖尿病患者外源性胰岛素给药量的方法
DK0859608T3 (da) * 1995-09-18 2004-06-14 Ligand Pharm Inc Behandling af NIDDM med RXR-agonister

Also Published As

Publication number Publication date
AP9901718A0 (en) 1999-12-31
PE104499A1 (es) 2000-01-13
CN1260715A (zh) 2000-07-19
IN189723B (fr) 2003-04-19
AR015894A1 (es) 2001-05-30
CN1133431C (zh) 2004-01-07
KR20010013843A (ko) 2001-02-26
OA11517A (en) 2004-02-04
IL133143A0 (en) 2001-03-19
AR012997A1 (es) 2000-11-22
MA26511A1 (fr) 2004-12-20
UA70299C2 (en) 2004-10-15
EA200000042A1 (ru) 2000-08-28
SK179399A3 (en) 2000-11-07
HUP0003260A2 (hu) 2001-05-28
ID23951A (id) 2000-06-08
EA004800B1 (ru) 2004-08-26
CO4940454A1 (es) 2000-07-24
EP0999837A1 (fr) 2000-05-17
JP2002504138A (ja) 2002-02-05
BR9810444A (pt) 2000-09-05
DZ2521A1 (fr) 2003-02-08
GB9712866D0 (en) 1997-08-20
TW587937B (en) 2004-05-21
BG104059A (en) 2000-10-31
ZA985237B (en) 2000-02-17
CA2294141A1 (fr) 1998-12-23
UY25050A1 (es) 2000-09-29
AP1287A (en) 2004-06-26
NO996265D0 (no) 1999-12-17
HUP0003260A3 (en) 2001-12-28
WO1998057636A1 (fr) 1998-12-23
NO996265L (no) 1999-12-17
PL343123A1 (en) 2001-07-30
TR199903095T2 (xx) 2000-08-21

Similar Documents

Publication Publication Date Title
EP0996444B1 (fr) Traitement du diabete a l'aide de thiazolidinedione et de metformine
US20030109553A1 (en) Treatment of diabetes with thiazolidinedione and metformin
US20080058388A1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
AP1287A (en) Treatment of diabetes with rosiglitazone and insulin.
EP0999845B1 (fr) Traitement du diabete a l'aide de thiazolidinedione et de sulfonyluree
US20040106543A1 (en) Treatment of diabetes with rosiglitazone and insulin
WO1999003478A1 (fr) Traitement du diabete avec du thiazolidinedione, un secretagogue d'insuline et un inhibiteur d'alpha glucosidase
NZ501345A (en) Treatment of diabetes mellitus with 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (2-12 mg) and an alpha-glucosidase inhibitor antihyperglycemic agent
WO1999003476A1 (fr) Traitement du diabete avec du thiazolidinedione et de la sulfonyluree
AU783539B2 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
NZ518076A (en) 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
AU1552102A (en) Treatment of diabetes with rosiglitazone and insulin
US20030073645A1 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
MXPA99012065A (en) Treatment of diabetes with rosiglitazone and insulin
NZ520542A (en) Treatment of diabetes with thiazolidinedione and metformin

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted